Listar por autor "Pinto-Medel, Mª Jesús"
Mostrando ítems 1-3 de 3
-
Candidate Gene Study of TRAIL and TRAIL Receptors: Association with Response to Interferon Beta Therapy in Multiple Sclerosis Patients
López-Gómez, Carlos; Pino-Ángeles, Almudena; Órpez-Zafra, Teresa; Pinto-Medel, Mª Jesús; Oliver-Martos, Begoña
; Ortega-Pinazo, Jesús; Arnáiz, Carlos; Guijarro-Castro, Cristina; Varadé, Jezabel; Alvarez-Lafuente, Roberto; Urcelay, Elena; Sánchez-Jiménez, Francisca María; Fernández Fernández, Oscar; Leyva-Fernández, Laura[et al.] (Public Library of Sciences, 2013)
TRAIL and TRAIL Receptor genes have been implicated in Multiple Sclerosis pathology as well as in the response to IFN beta therapy. The objective of our study was to evaluate the association of these genes in relation to ... -
Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients
García-León, Juan Antonio; Pinto-Medel, Mª Jesús; García-Trujillo, Lucía; López-Gómez, Carlos; Oliver-Martos, Begoña; Prat-Arrojo, Isidro; Marín-Bañasco, Carmen; Suardíaz-García, Margarita; Maldonado-Sánchez, Rafael; Fernández Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2011)
Killer cell immunoglobulin-like receptors (KIRs) are regulators of cytolytic activity of natural killer and certain T cells through interactions with human leukocyte antigen (HLA) class I ligands. KIRs have been shown to ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
Oliver-Martos, Begoña; Fernández Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, Mª Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (SAGE Journals, 2011)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ...